



ASX ANNOUNCEMENT

13 July 2007

Clinical Trial Update

Following significant shareholder enquiry, the Company provides an update of the status of the international clinical trial currently underway for HeartWare's HVAD™ Left Ventricular Assist Device.

Following recent successful implants at Hannover Medical Centre, Royal Perth Hospital and St Vincent's Hospital in Sydney, the HVAD™ pump has now been implanted in 16 patients. On a cumulative basis these patients have been supported by the device for over 2,400 days. The average support duration across the group exceeds 150 days per patient.

15 out of the 16 patients are alive and well, with all but the three most recent patients having long been discharged from hospital. Of the 16 patients, 7 have now successfully passed the primary endpoint of the clinical trial, namely survival to 180 days or to the point of undergoing heart transplantation. Three of our patients have received heart transplants, after being supported by their pumps for 427, 348 and 157 days respectively.

The pump continues to demonstrate very promising clinical results. We are confident of completing our 20 patient target enrolment in the trial over coming weeks.

About HeartWare

HeartWare is developing a family of proprietary circulatory assist devices to treat patients with heart failure. HeartWare's lead investigatory product, the HVAD™ device, is currently progressing through an international clinical trial. With a volume of 45cc, the HVAD™ device is the smallest "3rd generation" pump and the only full output device implantable routinely within the thoracic cavity.

HeartWare's miniaturization platform enables the development of smaller devices, potentially implantable by minimally invasive surgical techniques. Pre-clinical studies are underway for HeartWare's MVAD™ device, a pump one third the size of the HVAD™ device. HeartWare's IV-VAD, a pump one tenth the size of the HVAD™ device, is at early prototype stage.

For further information:

www.heartware.com.au

Howard Leibman

Director Corporate Development

HeartWare Limited

+61 2 9238 2064 / 0402 440644